Seung Edward, Mordes John P, Rossini Aldo A, Greiner Dale L
Program in Immunology and Virology,University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
J Clin Invest. 2003 Sep;112(5):795-808. doi: 10.1172/JCI18599.
Allogeneic hematopoietic chimerism leading to central tolerance has significant therapeutic potential. Realization of that potential has been impeded by the need for myeloablative conditioning of the host and development of graft-versus-host disease (GVHD). To surmount these impediments, we have adapted a costimulation blockade-based protocol developed for solid organ transplantation for use in stem cell transplantation. The protocol combines donor-specific transfusion (DST) with anti-CD154 mAb. When applied to stem cell transplantation, administration of DST, anti-CD154 mAb, and allogeneic bone marrow leads to hematopoietic chimerism and central tolerance with no myeloablation and no GVHD. Tolerance in this system results from deletion of both peripheral host alloreactive CD8+ T cells and nascent intrathymic alloreactive CD8+ T cells. In the absence of large numbers of host alloreactive CD8+ T cells, the transfusion that precedes transplantation need not be of donor origin, suggesting that both allospecific and non-allospecific mechanisms regulate engraftment. Agents that interfere with peripheral transplantation tolerance impair establishment of chimerism. We conclude that robust allogeneic hematopoietic chimerism and central tolerance can be established in the absence of host myeloablative conditioning using a peripheral transplantation tolerance protocol.
导致中枢耐受的异基因造血嵌合具有显著的治疗潜力。但由于需要对宿主进行清髓预处理以及移植物抗宿主病(GVHD)的发生,这种潜力的实现受到了阻碍。为了克服这些障碍,我们采用了一种为实体器官移植开发的基于共刺激阻断的方案用于干细胞移植。该方案将供体特异性输血(DST)与抗CD154单克隆抗体相结合。当应用于干细胞移植时,给予DST、抗CD154单克隆抗体和异基因骨髓可导致造血嵌合和中枢耐受,且无需清髓,也不会发生GVHD。该系统中的耐受是由于外周宿主同种异体反应性CD8 + T细胞和新生胸腺内同种异体反应性CD8 + T细胞的缺失所致。在没有大量宿主同种异体反应性CD8 + T细胞的情况下,移植前的输血不必来自供体,这表明同种特异性和非同种特异性机制均调节植入。干扰外周移植耐受的药物会损害嵌合的建立。我们得出结论,使用外周移植耐受方案,在不进行宿主清髓预处理的情况下,可以建立强大的异基因造血嵌合和中枢耐受。